Abstract: The invention provides a screening assay for selecting inhibitors of NFAT:Transcription factor interactions. The invention also provides compositions and methods for inhibiting immune response in a subject.

Abstract: A gas analyzer apparatus includes a device or platform for supporting a predetermined quantity of a reagent capable of reacting with a predetermined gas to cause a detectable change in a characteristic of the reagent, a reservoir adapted to retain the reagent, a dispenser for dispensing a controlled quantity of the reagent from the reservoir to a predetermined position on the device for supporting the predetermined quantity of the reagent, and a detector that detects the presence of the predetermined gas upon the predetermined gas and the controlled quantity of reagent reacting to cause a detectable change in a characteristic of the reagent detectable by the detector, the detector adapted to detect a change in the controlled quantity of the reagent by detecting the change in the characteristic through the predetermined quantity of the reagent.

Abstract: Isolated peptide fragments of the conserved regulatory domain of NFAT protein capable of inhibiting protein-protein interaction between calcineurin and NFAT, or a biologically active analog thereof are described. Isolated polynucleotides and gene therapy vectors encoding such peptide fragments are also described. In addition, methods for treating immune-related diseases or conditions and methods for high throughput screening of candidate agents are described. Pharmaceutical compositions are also provided.

Abstract: The present invention provides methods for identifying compounds capable of modulating anergy by inhibiting the production or activity of anergy associated E3 ubiquitin ligases or by altering the interaction between a ligase and its substrate.

Abstract: Isolated peptide fragments of the conserved regulatory domain of NFAT protein capable of inhibiting protein-protein interaction between calcineurin and NFAT, or a biologically active analog thereof are described. Isolated polynucleotides and gene therapy vectors encoding such peptide fragments are also described. In addition, methods for treating immune-related diseases or conditions and methods for high throughput screening of candidate agents are described. Pharmaceutical compositions are also provided.

Abstract: A gas analyzer apparatus includes a device or platform for supporting a predetermined quantity of a reagent capable of reacting with a predetermined gas to cause a detectable change in a characteristic of the reagent, a reservoir adapted to retain the reagent, a dispenser for dispensing a controlled quantity of the reagent from the reservoir to a predetermined position on the device for supporting the predetermined quantity of the reagent, and a detector that detects the presence of the predetermined gas upon the predetermined gas and the controlled quantity of reagent reacting to cause a detectable change in a characteristic of the reagent detectable by the detector, the detector adapted to detect a change in the controlled quantity of the reagent by detecting the change in the characteristic through the predetermined quantity of the reagent.

Abstract: Isolated peptide fragments of the conserved regulatory domain of NFAT protein capable of inhibiting protein—protein interaction between calcineurin and NFAT, or a biologically active analog thereof are described. Isolated polynucleotides and gene therapy vectors encoding such peptide fragments are also described. In addition, methods for treating immune-related diseases or conditions and methods for high throughput screening of candidate agents are described. Pharmaceutical compositions are also provided.

Abstract: Isolated peptide fragments of the conserved regulatory domain of NFAT protein capable of inhibiting protein-protein interaction between calcineurin and NFAT, or a biologically active analog thereof are described. Isolated polynucleotides and gene therapy vectors encoding such peptide fragments are also described. In addition, methods for treating immune-related diseases or conditions and methods for high throughput screening of candidate agents are described. Pharmaceutical compositions are also provided.

Abstract: Isolated peptide fragments of the conserved regulatory domain of NFAT protein capable of inhibiting protein-protein interaction between calcineurin and NFAT, or a biologically active analog thereof are described. Isolated polynucleotides and gene therapy vectors encoding such peptide fragments are also described. In addition, methods for treating immune-related diseases or conditions and methods for high throughput screening of candidate agents are described. Pharmaceutical compositions are also provided.